Ozempic vs Mounjaro: Which Is Better for Weight Loss?

Ozempic and Mounjaro are the two most talked-about weight loss medications today. Both have helped people achieve significant results, but they work differently and produce different outcomes. This article compares these medications to help you make an informed choice.

Understanding the Basics

Ozempic contains semaglutide, a GLP-1 receptor agonist made by Novo Nordisk. It was originally approved for type 2 diabetes but became famous for its weight loss effects.

Mounjaro contains tirzepatide, a dual GLP-1/GIP receptor agonist made by Eli Lilly. It is the first medication in its class and produces the highest weight loss ever seen in pharmaceutical trials.

Head-to-Head Comparison

Weight Loss Comparison

The SURPASS-2 trial directly compared tirzepatide to semaglutide in diabetes patients. The results showed tirzepatide producing nearly double the weight loss at equivalent timepoints. In dedicated weight loss trials:

• Mounjaro® (15mg): Significant weight loss in published clinical studies
• Ozempic® (2mg): Moderate weight loss in clinical studies
• Wegovy® (2.4mg semaglutide): Meaningful weight loss in clinical studies

For a 100kg Nigerian seeking weight loss:

• On Ozempic: Expect to lose approximately 10-14kg
• On Mounjaro: Expect to lose approximately 20-23kg

Why Is Mounjaro More Effective?

The key difference is Mounjaro's dual mechanism. By activating both GLP-1 and GIP receptors, it produces stronger appetite suppression and may have additional effects on fat metabolism and energy expenditure.

GIP activation adds benefits that semaglutide cannot provide:

• Enhanced fat mobilization from adipose tissue
• Potentially better preservation of muscle mass
• Stronger satiety signals through different brain pathways
• Possible metabolic rate preservation during weight loss

For the detailed science, see our article on tirzepatide vs semaglutide.

Side Effects Comparison

Both medications share similar gastrointestinal side effects. However, clinical data suggests Mounjaro may be slightly better tolerated despite producing greater weight loss:

• Nausea: More common with Ozempic (~40%) than Mounjaro (~30%)
• Diarrhea: Similar rates, around 20-30%
• Vomiting: More common with Ozempic
• Constipation: Similar rates

For management tips, see our guides on GLP-1 side effects and managing nausea.

Which Should You Choose?

Consider Ozempic if:

• Mounjaro is not available to you
• You have successfully used semaglutide before
• Your healthcare provider specifically recommends it

Availability in Nigeria

Neither brand-name Ozempic® nor brand-name Mounjaro® is registered with NAFDAC. Both semaglutide and tirzepatide are available through compounding pharmacies as these are FDA-approved active ingredients.

Given the significant efficacy difference, most Nigerians who have access to both options choose tirzepatide. Learn more about getting GLP-1 medications in Nigeria.